Exhibit 99.2

 January 2022  A subsidiary of  CULTIVATED by SCIENCE 

 Forward Looking Statement  This presentation contains "forward-looking statements" relating to future events, and Canonic Ltd (the “Company”) and its parent, Evogene Ltd. (“Evogene”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as “believe”, “expect”, “anticipate”, “should”, “planned”, “estimated”, “intend” and “potential” or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene’s and our technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors”. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. 

 INTRODUCTION 

 43  OUR VISION  Commercialize effective, precise and stable medical cannabis products, based on decoding plant genetics, for optimized therapeutic effect 

   Global Cannabis Market    20.4  26  32  38  46.8  43     Source: Arcview Market Research/BDSA 

   Market Challenges  STABILITY  Substantial variationswithin varieties produceinconsistent products andtherefore, inconsistent results  YIELD  Low yield of active compounds affects income per sq foot  SPECIFICITY  Significant knowledge gap prevents matching active compounds to medical indications     The opportunity : With state-of-the-art plant genomic expertise, major market challenges can be solved 

   The opportunityFrom Plant Genetics – To Medical Cannabis Products  Plant genetics know-how is the basis for development of premium Cannabis varieties  Premium varieties can lead to novel medical Cannabis products addressing market challenges      

 PRODUCTS 

 Optimize consumer traits [e.g. inflorescence size, density, scent]  Increased active compounds[e.g. Increased trichomes prevalence]   MetaYield+ Stable enhancement of total plant compoundsFocus on agronomic and consumer traits  Compound profile focus [e.g. CBG, CBC]  Medical indication focus [e.g. Pain & Inflammation]  Precise+ Stable enhancement of specific active compoundsFocus on therapeutic traits               Variety Families Under Development  First products in the market  Next generation products 

   MetaYield+ Varieties – The G-nnovation series   *IMC- Israel Medical Cannabis agency in the Ministry of Health  Now available in more than 70 pharmacies in Israel   IMC* category T15C3  18 % THCHigh consumer rank   IMC* category T20C4  21 % THCHigh consumer rank   Use   Day   Scent   Pine Lemon   Active compounds   THC18%,CBD>0.1   Use   Night  Active compounds   THC21%,CBD>0.1   Scent   Pine Sweet   Product 1: G150  Product 2: G200 

   Precise+: Medical indication focus        Indication: Inflammation  Pre-clinical study: Hadassah medical center  Status: product development   Expected launch: 2023  Indication: Pain  PRODUCT 2 (under development)   Pre-clinical study: Migal research center  Status: product development   Expected launch: 2023  Target market size in 2023*: Israel $280 M, EU $750M  Target market size in 2023*: Israel $115M, EU $300M  *Company estimate, based on current market sale prices and data published by Israeli Ministry of Health regarding number of medical cannabis users in Israel and by Prohibition Partners in The European Cannabis Report Feb 2020.                      PRODUCT 1 (under development)  

   Collaboration With Tikun Olam-Cannbit  Targeting specific compound profile      Pre-clinical study: under evaluation  Status: product development           Precise+: Specific compound profile   PRODUCT 3 (under development)  

 Technology 

   The Genomic Power – improving performance   The potential:Improving plant traits through advanced breeding   Cultured Maze  Wild Maze  Example – Corn is considered a leading commercial crop Wild corn went through genetic changes before it became a commercial crop.   The challenge: Connect genomic elements to traitsShorten the development time   The opportunity => BIG DATA AND COMPUTATIONAL BIOLOGY  

 Computational Genomics Combining deep scientific know-how with Big Data and AI technology to tailor the plant genetics for improvement of plant traits and development of unique cannabis products  When Data Meets Computational Biology   BIG DATA  Genomics  AI 

   Canonic proprietary database and assets  >1000 characterized lines (>17.5*106 data points)  Genotype  Phenotype   Pre-clinical  Chemotype     Genetic markersFor traits of interest (e.g. active compounds)  Diverse Breeding populationsProprietary hybrids  Accumulated assets  Genetic bank 'Mother' plants, seeds, tissue culture 

   Products         BIG DATA  AI  Computational genomics tools        Plant genomics database with >109 data points on > 200 plants   Proprietary Cannabis genomic & chemical data on > 1000 lines  Pre-clinical data    Big Data & AI transforming Data to Know-how  

   The genomic power – 20% increase in THC content    THC content (%)  Developing next generation MetaYield+ products By leveraging our unique proprietary know-how and database, within 12 months we have:Improved the target trait by 20%Reached 6-fold increase in number of cannabis lines with >20% THC content  20% THC increase   Initial population  New hybrids  Frequency in population      +20%  X6 lines    20%    THC 

   Demonstrated Capabilities Along The Development Value Chain  Large genetic & breeding collections  Certified Propagation farm   State of the art data collection tools  Fully equipped labs & tissue culture rooms  Advanced-breeding facility   World-class computational genomics  Canonic holds computational genomics capabilities and the full plant infrastructure to execute 

 Business model 

   Patients  VarietiesDevelopment  R&D Facilities  Distribution  RegionalDistributors  Seeds & SeedlingProduction  PropagationFarms  Sales& Marketing  Manufacturing  Extraction &Formulation  CannabisCultivation  Cultivators  ACTIVITY                            B2B2C marketing to Pharmacies   Seed to Sale Powered by Genomics  Cannabis Value Chain 

   Reduced time to market and higher profitability by leveraging our proprietary genomic expertise and outsourcing downstream elements of the value chain   Patients  VarietiesDevelopment  Active R&D Facilities  Distribution  RegionalDistributors  Seeds & SeedlingProduction  Active PropagationFarm  Sales& Marketing    Manufacturing  Extraction &Formulation  CannabisCultivation  Cultivators  ACTIVITY                Active suppliers  Canonic in the Cannabis Value Chain  Active suppliers  Service providers               Active suppliers 

 Summary 

   Team  Dr. Inbal Dangoor  VP R&D  Guy Adler  VP Product  Yonatan Wegman  Head Agronomist  Dr. Michi Brog  Plant Breeder  Dr. Arnon Heyman  CEO  Elena Huly  Marketing & Sales  Dr. Haleli Sharir   Clinical Research Director   Tanya Damm Bokobza  EVP Business Development 

   Directors and Advisory Board  Board of directors   Ofer Haviv Chairman of the board   Evogene President & CEO  Raanan CohenBusiness strategy   Former CEO Koor Industries   Prof. Yossi TamCannabinoid clinical research   Director, Multidisciplinary Center for Cannabinoid Research of the Hebrew University  Dr. Yariv BrotmanPlant metabolic pathways   Ben Gurion University & Max Planck Institute of Molecular Plant Physiology   Dorit KreinerFinance  Evogene CFO  Nirit ElyovichMarketing strategy   Senior marketing specialist with over 20 years of B2C experience  Shai LeviatovPlant breeding   Commercial varieties breeding for more than 30 years in top leading multinational seeds companies   Advisory board  Omri OferPharmaceutical distribution  Former CEO Chemipal  

   Company Milestones      Establishment  POC & Go-to-Market   MetaYield+ Pre-Commercial   MetaYield + Commercial  Precise + Market entry   Market entry N. America  2019  2020  2021  2022            1  2  3  4  5  Infrastructure, Genetic collection     Go to Market- IL     Initial sales-IL    2023  2024 and onward  Target Markets  IL  IL, EU  IL, EU, N. America       Go to Market- EU    Initial sales-EU    Initial sales-NA    Value creation   Time 

   Canonic’s distinct market advantage is in mapping, decoding and stabilizing cannabis genetics for better health.Canonic holds exclusive rights to Evogene’s (NASDAQ, TASE: EVGN) state-of-the-art computational genomics technology, for product development for the Cannabis market segment.Canonic’s first two products, G-150 and G-200, were launched in Israel in October 2021. Next generation products are expected to focus on 2 major medical indications, pain and inflammation, which represent > 60% of the medical market*.Canonic aims to enter the EU market during 2023.  Summary   *Company estimate, based on data published by Israeli Ministry of Health regarding number of medical cannabis users in Israel 

 THANK YOU  CULTIVETED by SCIENCE